Alpha Tau to Present at the Jefferies Radiopharma Innovation Summit
25 mars 2024 08h50 HE
|
Alpha Tau Medical Ltd.
JERUSALEM, March 25, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha...
Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update
07 mars 2024 16h01 HE
|
Alpha Tau Medical Ltd.
- Positive interim safety and feasibility data from pancreatic cancer study in Montreal, with initial signs of potential dose response findings - - ReSTART U.S. multi-center pivotal trial currently...
Alpha Tau to Participate in Barclays 26th Annual Global Healthcare Conference
26 févr. 2024 08h30 HE
|
Alpha Tau Medical Ltd.
JERUSALEM, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™,...
Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference
20 déc. 2023 09h15 HE
|
Alpha Tau Medical Ltd.
- The overview presentation will review some of the Company’s recent achievements, including highly promising interim results from the Company’s pancreatic cancer safety and feasibility trial as well...
Alpha Tau to Participate in Sidoti Small-Cap Conference
29 nov. 2023 08h30 HE
|
Alpha Tau Medical Ltd.
JERUSALEM, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™,...
Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer
28 nov. 2023 08h30 HE
|
Alpha Tau Medical Ltd.
- Interim data read-out of the first five treated patients demonstrated successful delivery in all five cases, as well as no product-related Serious Adverse Events - - First five patients received...
Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer
20 nov. 2023 08h30 HE
|
Alpha Tau Medical Ltd.
JERUSALEM, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, and HekaBio K.K....
Alpha Tau Medical Announces Third Quarter 2023 Financial Results and Provides Corporate Update
16 nov. 2023 16h30 HE
|
Alpha Tau Medical Ltd.
- Treated the first patient with advanced inoperable pancreatic cancer at Hadassah Medical Center in Israel in September, alongside safety and feasibility trial in similar indication currently...
Alpha Tau to Participate in November Investor Conferences
01 nov. 2023 08h30 HE
|
Alpha Tau Medical Ltd.
JERUSALEM, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™,...
Alpha Tau Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing Facility
30 oct. 2023 08h30 HE
|
Alpha Tau Medical Ltd.
JERUSALEM, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™,...